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ALAD Porphyria Is a Conformational Disease
Eileen K. Jaffe and Linda Stith
ALAD porphyria is a rare porphyric disorder, with five documented compound heterozygous patients, and it is caused
by a profound lack of porphobilinogen synthase (PBGS) activity. PBGS, also called “d-aminolevulinate dehydratase,” is
encoded by the ALAD gene and catalyzes the second step in the biosynthesis of heme. ALAD porphyria is a recessive
disorder; there are two common variant ALAD alleles, which encode K59 and N59, and eight known porphyria-associated
ALAD mutations, which encode F12L, E89K, C132R, G133R, V153M, R240W, A274T, and V275M. Human PBGS exists
as an equilibrium of functionally distinct quaternary structure assemblies, known as “morpheeins,” in which one func-
tional homo-oligomer can dissociate, change conformation, and reassociate into a different oligomer. In the case of
human PBGS, the two assemblies are a high-activity octamer and a low-activity hexamer. The current study quantifies
the morpheein forms of human PBGS for the common and porphyria-associated variants. Heterologous expression in
Escherichia coli, followed by separation of the octameric and hexameric assemblies on an ion-exchange column, showed
that the percentage of hexamer for F12L (100%), R240W (80%), G133R (48%), C132R (36%), E89K (31%), and A274T
(14%) was appreciably larger than for the wild-type proteins K59 and N59 (0% and 3%, respectively). All eight porphyria-
associated variants, including V153M and V275M, showed an increased propensity to form the hexamer, according to
a kinetic analysis. Thus, all porphyria-associated human PBGS variants are found to shift the morpheein equilibrium for
PBGS toward the less active hexamer. We propose that the disequilibrium of morpheein assemblies broadens the definition
of conformational diseases beyond the prion disorders and that ALAD porphyria is the first example of a morpheein-
based conformational disease.
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The porphyrias are diseases resulting from the abnormal
functioning of the enzymes of heme biosynthesis.1 ALAD
porphyria (MIM 125270), also known as “Doss por-
phyria,” is a very rare porphyric disorder linked to a pro-
found lack of porphobilinogen synthase (PBGS [EC
4.2.1.24]) activity.2 PBGS, also known as “d-aminolevuli-
nate dehydratase” (ALAD), is encoded by the ALAD gene.3
There are two common alleles for ALAD, which encode
either lysine or asparagine at amino acid position 59,4 and
the relative frequencies of these alleles vary among pop-
ulations.5–11 ALAD porphyria is a recessive disorder; the
described patients are compound heterozygotes, and there
are a total of eight known porphyria-associated ALAD al-
leles.12–26 Of five documented compound heterozygotes,
one was an infant, three were males who became symp-
tomatic during adolescence, and one was a male who re-
ceived the diagnosis during early adulthood. On the basis
of an analysis of a small population, it has been estimated
that the prevalence of individuals with 50% of normal
PBGS activity, putatively caused by one aberrant ALAD
allele, is ∼2% in the normal asymptomatic population.27
That study suggested that most instances of compound
heterozygosity in ALAD result in spontaneous abortions.
Heme biosynthesis in humans is an essential metabolic
function controlled predominantly at the first committed
step, which is the mitochondrial synthesis of 5-amino-
levulinic acid from succinyl–coenzyme A (CoA) and gly-
cine.28 PBGS catalyzes the asymmetric condensation of
two molecules of 5-aminolevulinic acid, to form por-
phobilinogen.29 Mammals contain as much as 100-fold
more enzyme activity than is necessary for required heme
formation,30 and alternative possible moonlighting func-
tions for PBGS include roles in proteosome-directed pro-
tein degradation and in chaperone-assisted protein
folding.31,32 Before the characterization of the porphyria-
associated hexameric human PBGS variant F12L, the wild-
type protein had been well characterized as a homo-
octamer.33 Crystal structures had been deposited for
homo-octameric forms of PBGS from human, yeast, Esch-
erichia coli, and Pseudomonas aeruginosa; these, along with
high sequence conservation for PBGS throughout all king-
doms, led to the hypothesis that all PBGSs are homo-
octameric in structure and assembly.33 However, some size-
exclusion chromatography data from the 1960s and 1970s
had suggested other possible quaternary assemblies, par-
ticularly for the proteins from photosynthetic organ-
isms,34,35 in which PBGS also functions in chlorophyll bio-
synthesis. Characterization of the naturally occurring
low-activity human PBGS variant F12L revealed its hex-
americ assembly36,37 and led to revolutionary new insights
into the dynamic flexibility of homo-oligomeric pro-
teins.38,39 The F12L mutation, which has been documented
in two unrelated white individuals,13,37 was shown, by x-
ray crystallographic analysis, to give rise to a dramatic
rearrangement in the secondary structure of the N-ter-
minal arm domain of the protein, which resulted in as-
sembly into a hexamer.36 As illustrated in figure 1, the
wild-type protein structure is predominantly a homo-
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Figure 1. Equilibrium of human PBGS morpheeins. The human
PBGS quaternary structure isoforms are the high-activity octamer
(wild-type protein [PDB code 1E51] [shades of red]), the transient
hugging dimer, the transient detached dimer, and the low-activity
hexamer (F12L variant [PDB code 1PV8] [shades of blue]).36,38,39
Detailed ribbon diagrams of the assembly of the octamer and hex-
amer have been published elsewhere.36,39



















Octameric Km Hexameric Km
K59 … 100e 62f 100:0 2.2 .20 …
N59 … 69.9e 41f 97:3 3.3 .17 …
N59/C162A … ND 42f (100) 95:5 3.6 .25 …
F12Lg CPOh .5e !.1 (.2) 0:100i 6.3 … 17
E89Kg C132R ∼10e 27 (64) 69:31 1.4 .16 6.6
C132Rg E89K ∼4e .11 (.3) 64:36 3.0 .13 20
G133Rg V275M 8.1 ∼5 (12) 52:48 5.6 .19 8.9
V275Mg G133R 1.2 ∼35 (83) 94:6 4.1 .11 1.4
R240Wg A274T 3.5e ∼2 (4.8) 20:80 ∼4.0 .07 35
A274Tg R240W 19.3e ∼25 (60) 86:14 2.8 .18 4.0
V153Mg 818delTCj 41e ∼16 (38) 95:5 7.3 .10 3.1
a Taken from previous studies.12–22,24–26 ND p not determined.
b The maximum specific activity (mmol h1 mg1) seen in the octamer peak eluting from the Sephacryl S-300 column (Q Sepharose column for
G133R). This value does not necessarily reflect the specific activity at the optimal pH for each mutant, and it does not necessarily reflect the Vmax
values that are associated with the reported Km values. The values in parentheses are percentage activity.
c As estimated during the purification procedures from native gels of the Phenyl Sepharose–purified protein and/or from the elution profile from
the Q-Sepharose column.
d Fit to either the Michaelis-Menten single hyperbolic equation or the double-hyperbolic model that describes a mixture of two species (fig. 3).
e Expression as a fusion protein with glutathione S-transferase.
f The specific activities varied from one purification to the next, showing variation up to 30%.
g Mutations were prepared in the N59/C162A background.
h CPO p coproporphyrinogen oxidase deficiency.
i The activity of a small amount of protein (1%–5%) that ran like octamer had characteristics of E. coli PBGS, pH 7, activity stimulated by Mg.
j Encodes a truncation mutant.
octamer, composed of four hugging dimers, and the F12L
protein structure is a homo-hexamer, composed of three
detached dimers. The most significant difference between
the octameric and hexameric assemblies is the orientation
of an ab-barrel domain (residues 25–330) with respect to
an N-terminal arm domain (residues 1–24) of each sub-
unit. Although the F12L mutation is not at the enzyme
active site, the quaternary structure change can be seen
to destabilize the active-site lid and to account for the low
activity of the hexamer.40 Detailed biochemical and bio-
physical analysis of the hexamer and octamer of human
PBGS showed that these isoforms are in dynamic equilib-
rium with each other and that catalytic turnover facilitates
this equilibration.39,41 Designed, synthetic single–amino
acid changes other than F12L were also shown to alter the
equilibrium of human PBGS quaternary structure iso-
forms38; the R240A mutation favors assembly of the hex-
amer, and the W19A mutation restricts assembly beyond
the dimer. These studies led to the introduction of the
term “morpheeins.”39,41
Morpheeins is a recently introduced term used to de-
scribe an ensemble of functionally distinct, native qua-
ternary structure assemblies of a given homo-oligomeric
protein, in which one functional oligomer can dissociate,
change conformation, and then reassociate into a struc-
turally and functionally different oligomer.38,39,41 Mor-
pheeins were initially described as one possible structural
basis for allosteric regulation of protein function.41 Mor-
pheeins are like prions, in that they are proteins that can
exist in more than one quaternary structure assembly.
However, unlike the established prion phenomenon, the
equilibration of alternate morpheeins is a readily revers-
ible, physiologically relevant mechanism for control of
protein function.41 For human PBGS, the morpheein
forms are the high-activity octamer and the low-activity
hexamer described above.36,38,39,41
The existence of morpheeins of human PBGS raised the
question of whether the naturally occurring porphyric
mutations in human PBGS also alter the equilibrium of
quaternary structure isoforms. The classic conformational
diseases, such as Alzheimer disease, occur when a func-
tional protein with a globular structure becomes altered
into a structure that oligomerizes into fibers, with disas-
trous physiologic consequences.42 Similar phenomena are
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Figure 2. Spatial location of the porphyria-associated mutations of human PBGS. The crystal structure of human PBGS (PDB code
1E51) contains an asymmetric hugging dimer in the unit cell; the two subunits differ predominantly in their regions of disorder. The
more highly ordered monomer is illustrated (in stereo) by use of a light-gray strand to illustrate the backbone. Product is seen bound
at the enzyme active site (wire-frame representation with Corey, Pauling, Koltun [CPK] coloring), and known human variations are
shown using space-filling representation. Lys59, which has some disorder, is green, Phe12 is magenta, Ala274 is red, Gly133 is blue,
Arg240 is yellow, Cys132 is cyan, Glu89 is orange, Val153 is pink, and Val275 is purple.
associated with the infectious prion disorders, such as
transmissible spongioform encephalopathies in both hu-
mans and animals.43 It has recently been suggested that
the disequilibrium of morpheein forms may constitute a
broader definition of conformational diseases.38 Here, we
address whether the defective activity of the eight por-
phyria-associated human PBGS variants,13–22,24–26,37 which
are F12L, A274T, V153M, G133R, R240W, V275M, C132R
and E89K, is related to the ability of this protein to in-
terconvert between functionally distinct morpheeins. We
asked whether these mutations have a conformational ef-
fect that alters the morpheein equilibrium for human
PBGS. Figure 2 illustrates the location of these amino acids
on one subunit of the wild-type octameric human PBGS
crystal structure (Protein Data Bank [PDB] code 1E51). Ta-
ble 1, which documents the characteristics of these vari-
ants, includes the combinations of mutations found in
patients with diagnosed porphyria. Our results led us to
propose that ALAD porphyria is the first identified mor-
pheein-based conformational disease.
Material and Methods
Plasmid Preparation, Protein Production, and Purification
The plasmids used for the expression of N59, K59, N59/C162A,
and F12L were described elsewhere.36,44,45 The plasmids for the
other human porphyria-associated ALAD alleles were prepared by
mutagenesis with the use of the QuikChange site-directed mu-
tagenesis kit (Stratagene), by starting with a pET3a-based plasmid
containing the synthetic gene for human PBGS wild-type variant
N59/C162A.45 The mutagenic primers are listed in table 2. All
resultant plasmids were sequenced in both directions throughout
the gene. Expression and purification of human PBGS and its
variants were as described elsewhere.38 The purification from the
soluble component of the lysed bacterial cells consisted of am-
monium sulfate fractionation (20%–45%), hydrophobic affinity
chromatography with the use of Phenyl Sepharose (GE Health-
care), anion-exchange chromatography with the use of Q Se-
pharose (GE Healthcare), and size-exclusion chromatography
with the use of Sephacryl S-300 (GE Healthcare). The various
human PBGS morpheeins separate from each other on the Q
Sepharose column.36,38,39 For those purified proteins that had a
higher-than-expected specific activity, it was further confirmed
that they contain the desired mutation by subjecting them to
tryptic digestion (for A274T, V275M, and G133R) or AspN pro-
tease digestion (for V153M) and mass spectrometric analysis, as
we have done elsewhere.39
Assessment of the Morpheein Equilibrium for the Resultant
Proteins
Initial assessment of the quaternary structure distribution for
each protein preparation was based on the elution profile from
the Phenyl Sepharose and/or Q Sepharose columns and on the
mobility during native-gel electrophoresis36,38,39 (table 1 and fig.
3). In some cases, individual fractions were analyzed by native
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E89K CGC GTT CCA AAG GAT aAg CGG GGC AGC GCA GCC GGC TGC GCT GCC CCG cTt ATC CTT TGG AAC GCG
C132R CAC GGT CAC cGC GGT CTC CTG AGC GAG CTC GCT CAG GAG ACC GCg GTG ACC GTG
G133R CAC GGT CAC TGC cGT CTC CTG AGC GAG AAC GTT CTC GCT CAG GAG ACg GCA GTG ACC GTG
V153M CGC CAG CGG TTA GCT GAG aTG GCC TTG GCG CGC CAA GGC CAt CTC AGC TAA CCG CTG GCG
R240W CGT GCT GTG GAC tGG GAT GTA CGG GAA GGC GCC TTC CCG TAC ATC CCa GTC CAC AGC ACG
A274T GAC TTG CCG CTC aCC GTG TAT CAC GTG AGC GCT CAC GTG ATA CAC GGt GAG CGG CAA GTC
V275M GAC TTG CCG CTC GCC aTG TAT CAC GTG AGC GCT CAC GTG ATA CAt GGC GAG CGG CAA GTC
Figure 3. Purification and quantification of the morpheeins of human PBGS. A, General purification scheme for human PBGS. There
was only one pool collected from the Phenyl Sepharose column for some proteins. B, Q Sepharose separation of the hexameric and
octameric human PBGS, shown using absorbance (Abs) and specific activity values. For the wild-type (WT) variant N59/C163A (dotted
line), the single pool from the Phenyl Sepharose column was run on the Q Sepharose column, which separated hexamer (WT 6-mer)
and octamer (WT 8-mer). The mobility of the F12L variant is coincident with wild-type hexamer.36,39 For the porphyria-associated variant
E89K (solid line), the early pool from the Phenyl Sepharose column was applied to the Q Sepharose column, and the separation of
hexamer (E89K 6-mer) and octamer (E89K 8-mer) is shown. Identification of the quaternary states is based on a fully consistent body
of data that includes x-ray crystal structures, pH activity profiles, Km and Vmax values, dynamic light scattering, and relative mobility
on native gels. C, A 12.5% acrylamide native PhastGel, showing separation of the morpheeins of human PBGS. The difference in mobility
between the wild-type and E89K samples is the surface charge difference caused by the mutation. The E89K hexamer and octamer pools
were concentrated by ultrafiltration before the PhastGel was run.
PAGE. Prior experience with both natural and synthetic mutants
established the expected elution time and electrophoretic mo-
bility for the octamer, hexamer, and dimer for those mutations
that are neutral (A274T, V153M, and V275M).36,38 The octameric
and hexameric morpheeins of the naturally occurring K59 variant
(1 charge difference) set the expected elution time and electro-
phoretic mobility for the 1 charged porphyria-associated mu-
tations C132R and G133R. The morpheeins of our previously
characterized synthetic mutant R240A (1 charge difference) set
the expected elution time and electrophoretic mobility for the
porphyria-associated mutation R240W. A standard was not avail-
able for the E89K variant (2 charge difference), but the two
bands observed by native-gel electrophoresis followed the ex-
pected pattern (see fig. 3). Molecular size was confirmed during
the final purification step, which was a Sephacryl S-300 column;
however, such columns cannot easily separate proteins that differ
in size by a factor !2. Final assessment was based on a kinetic
characterization relative to wild-type human PBGS, which is pre-
dominantly an octamer; F12L, which is a stable hexamer; and
the previously described synthetic mutant R240A, which is a
metastable hexamer.36,38
Results
A summation of the results for each of the mutations is
given in table 1. The details are described below.
Chromatographic Behavior
To determine the effect of the mutations on the octamer-
hexamer equilibrium for human PBGS, we took advantage
of our prior knowledge that these quaternary isoforms can
be separated from each other by ion-exchange chromatog-
raphy.36,38,39 All the human PBGS variants behaved like the
wild-type protein during the Phenyl Sepharose step of the
purification, for which a schematic is shown in figure 3A.
Phenyl Sepharose chromatography provides a partial sep-
aration of the octamer (enriched in the earlier part of the
peak) and the hexamer (enriched in the later part of the
peak). For those samples in which both octamer and hex-
amer were apparent from a native-gel analysis of the
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Figure 4. Determination of Km values at pH 7 for the variants of
human PBGS. Data are fitted to the hyperbolic Michaelis-Menten
equation (dashed lines) and to the double-hyperbolic equation
(solid lines); the latter suggests a mixture of two species with two
different Km values. Data are presented for the wild-type variant
K59 (black circles); for C132R (magenta triangles), which shows a
significant propensity to exist as a hexamer during the purification
(see main text); and for V153M (blue squares) and V275M (red
diamonds), which did not show significant hexamer in the puri-
fication. The superior fit to the double-hyperbolic equation is
shown for C132R, V153M, and V275M.
Phenyl Sepharose pooled fractions, it was possible to
achieve a near-baseline separation of the hexameric and
octameric assemblies by Q Sepharose chromatography, as
described elsewhere36,38 (fig. 3B). Chromatographic sepa-
ration was confirmed by native-gel analysis (fig. 3C). The
surface charge difference between N59/C162A and the
K59 and E89K variants caused both the hexamer and the
octamer of the variants to elute earlier in the gradient (at
∼22 min and ∼31 min, respectively). For all other variants,
where the structure suggests that the mutation will not
alter surface charge, the chromatographic mobility of the
hexamer was fairly tight (214–224 min). For the octamer,
however, the elution behavior spanned a larger time range
(244–278 min) and suggested that these variants may dif-
fer somewhat in the structure of the octamer, perhaps in
the relative mobility of charged surface loops. Table 1 in-
cludes the observed ratio of octamer to hexamer, based
on information from the Phenyl Sepharose separation, the
Q Sepharose separation, and native PAGE analysis. The
wild-type variants K59, N59, and N59/C162A all purified
predominantly as octamer, with 3%–5% appearing as hex-
amer for the N59-containing variants. For the mutants
F12L and R240W, the morpheein equilibrium was shifted
far toward the hexameric assembly, at 100% and 80% hex-
amer, respectively. The variants E89K, C132R, and G133R
each showed significantly more hexamer (31%–48%) than
did the wild type. These ranges may not be significantly
different from each other, since we have established that
the octamer-hexamer equilibrium is affected by sub-
strate,38,39 which is known to be present in the E. coli ex-
pression host. The variant A274T shows only a slightly
higher propensity for hexamer formation (14%) than does
the wild type, and the variants V275M and V153M each
have little more hexamer than do the wild-type variants
N59 and N59/C162A. Hence, from the chromatographic
behavior, we can conclude that the mutations F12L,
R240W, E89K, C132R, and G133R favor the hexamer-
ic assembly significantly more than do the wild-type
variants.
Kinetic Behavior of the Naturally Occurring Human PBGS
Variants
It is established that the kinetic constants Km and Vmax
differ substantially between the predominantly octameric
wild-type human PBGS and the hexameric F12L vari-
ant36,39 (table 1). The difference in Km values, in particular,
can confirm the octameric or hexameric assembly of a
given variant and can provide information about whether
both assemblies exist concurrently in the assay mixture.
The Km value for the substrate d-aminolevulinate (ALA),
at pH 7, for the octameric wild-type proteins is in the
physiologically relevant range at 0.2 mM. In contrast, for
the hexameric F12L variant, the Km value is 17 mM, which
is well above the physiological range for substrate con-
centration. For the wild-type variants and F12L, when the
substrate concentration is varied over a wide range of con-
centration (from 10 mM to 10 mM), the data fit superbly
to the simple hyperbolic Michaelis-Menten equation36;
data for K59 are included in figure 4. This hyperbolic fit
is consistent with the presence of one assembly, either
octamer or hexamer, in the assay mixture. However, we
have shown that the wild-type proteins, when assayed at
elevated pH values (e.g., pH 9) do not show a simple hy-
perbolic relationship between substrate concentration and
reaction rate.41 Instead, at pH 9, the hexameric form is
favored, and the kinetic data fit well to a double-hyper-
bolic equation indicative of the coexistence of two forms
of the protein, one with a Km in the range of 0.2 mM
(octamer) and one with a significantly higher Km value
(hexamer).36,39 Unlike the wild-type variants, each of the
porphyria-associated mutations showed a superior fit to
the double-hyperbolic equation, even at the more phys-
iologically relevant pH 7. Figure 4 includes kinetic data at
pH 7 for the fraction of protein that purified on the Q
Sepharose column as the octamer, for the porphyria-
associated variants C132R, V153M, and V275M; they all
showed a superior fit to the double-hyperbolic equation.
The V153M and V275M variants are chosen for illustra-
tion because they did not show a significantly increased
amount of PBGS hexamer during the purification (table
1). The derived Km values at pH 7 for all the human PBGS
variants are included in table 1. In all instances, the data
for the porphyria-associated human PBGS variants fit best
to the double-hyperbolic equation, display a tight Km value
in the range 0.07–0.19 mM ALA, and display a higher Km
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Figure 5. pH activity profiles for human PBGS variants. A, Wild-type variants N59 (squares), K59 (downward-pointing triangles), N59/
C162A (circles), and K59/C162A (diamonds). Data are presented as percentage of maximal activity, to emphasize the similarity of these
three curves. B, Variants E89K (squares), V153M (upward-pointing triangles), A274T (diamonds), and V275M (downward-pointing triangles),
compared with the wild-type parent protein N59/C162A (circles). C, The predominantly hexameric variants F12L (circles) and R240W
(squares). D, Variants C132R (squares) and G133R (circles). Cys132 is a ligand to the essential catalytic zinc ion.
value in the range 1.5–35 mM ALA. These kinetic data can
be interpreted as evidence that all the porphyria-associ-
ated human PBGS variants have a morpheein equilibrium
that is shifted toward the hexamer, relative to that of the
wild-type variants.
One unexpected kinetic result was the relatively high
specific activity for some of the purified proteins, relative
to activities reported when these variants were first ex-
pressed in Chinese hamster ovary (CHO) cells (table
1).12,17,18,37 Unlike in previous studies, we used a bacterial
heterologous expression system to produce significant
quantities (∼20–50 mg) of each of the porphyria-associ-
ated human PBGS. Those variants characterized by un-
expectedly high activities were A274T, E89K, and V275M,
which had threefold, sixfold, and eightfold more activity,
respectively, than was reported for CHO cell expression.
Potentially significant differences between these two ex-
pression systems include the expression temperature,
which is 15C for the bacteria, and the cellular concen-
tration of the substrate ALA, for which there is tight con-
trol in mammalian tissues.46 Since we have shown that
enzymatic activity can shift the human PBGS morpheein
equilibrium toward the octamer,38,39 the ready availability
of ALA in the bacterial expression system may have fa-
vored formation of the more active octameric assembly.
pH Activity Relationships for the Naturally Occurring
Human PBGS Variants
Previous studies established a dramatic difference between
the pH activity relationship of the predominantly octa-
meric wild-type human PBGS and the hexameric variant
F12L.36,39 It was established that the altered pH activity
relationship was a result of the quaternary structure
change, not the specific F12L mutation.36,38 To expand on
these studies, the specific activity of the remaining nat-
urally occurring human PBGS variants was determined as
a function of pH by use of a fixed substrate concentration
of 10 mM and an assay time of 5 min for V275M, A274T,
R240W, V153M, and G133R; 6 min for K59; 7 min for
E89K, N59, and N59C162A; and 3 h for C132R (fig. 5).
Because the Km for the substrate ALA varies dramatically
between the octameric and hexameric assemblies of hu-
man PBGS, it is important to point out that the data in
figure 5 reflect only specific activity and not Vmax values.
Furthermore, using the synthetic mutant R240A, we have
established that the equilibrium between the low-Km oc-
tamer and the high-Km hexamer is pH dependent.
38
Although the absolute specific activity of the wild-type
variants is not constant (table 1), the shape of the pH
activity profile is identical for N59, K59, and N59C162A
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(fig. 5A). The pH activity profiles were obtained for the
purified octameric components of the high-activity vari-
ants E89K, V153M, A274T, and V274M; these profiles are
all similar to that of the wild-type variant (fig. 5B), where
there is a pKa value of pH ∼6 and a second pKa value of
pH ∼8. The most notable variation from this trend is in
the second pKa value for E89K, which is shifted to pH !7.5.
The pH activity profile for the predominant hexameric
component of the R240W variant is comparable to that
for the hexameric F12L variant (fig. 5C). On the basis of
our work with the synthetic mutant R240A,38 we interpret
the activity of R240W in the pH range 6–7 as the result
of the propensity of the substrate ALA to pull the equi-
librium toward the octameric form.38 According to this
interpretation, longer assay times would be predicted to
result in higher activity at this slightly acidic to neutral
range of pH values. The pH activity profiles for C132R and
G133R—for both, it has been proposed that they disrupt
binding of the essential catalytic zinc ion—are also com-
pared (fig. 5D), and both are quite different from the pH
activity profiles for the other natural human PBGS vari-
ants. In these cases, because the catalytic zinc is compro-
mised, we cannot expect to interpret the pH activity
relationship on the basis of the quaternary structure
assembly alone.
Discussion
D. Shemin’s early studies on the enzymes of heme bio-
synthesis revealed that PBGS, then called “d-aminolevu-
linate dehydratase,” was present in tissues at levels far
greater than what appeared to be required for its function
in heme biosynthesis.30 This is consistent with the later
clinical observations that patients with ALAD porphyria
have more than one genetic aberration.12–15,17,18,21,25,26
When parents or siblings of these patients were available
for analysis, those relatives with only one aberrant gene
were found to have ∼50% normal PBGS activity in blood,
but these relatives did not have porphyria. The F12L mu-
tation was first discovered in an asymptomatic hetero-
zygous infant during a screen for hereditary tyrosinemia.37
The screen is based on the fact that a metabolic by-product
in patients with tyrosinemia is succinylacetone, which is
a potent inhibitor of PBGS. The infant showed 12% nor-
mal PBGS activity. F12L is now known to produce a low-
activity hexameric form of PBGS that is dramatically
different from the wild-type octameric assembly.36 Coex-
pression of wild-type human PBGS and F12L demon-
strated the ready assembly of heteromeric oligomers com-
prising two different kinds of human PBGS subunits—
some that contained phenylalanine at position 12 and
some that contained leucine. Such heteromeric oligomers
would be expected to exist in compound heterozygous
patients with ALAD porphyria. In our previous studies,
the hetero-octamers composed of wild type and F12L ex-
hibited kinetic behavior like that of the wild-type octamer,
and the heterohexamers were like the F12L homohex-
amer, but both were shown to exist in a dynamic equilib-
rium. Similar dynamic equilibria of heteromeric oligomers
would be expected to exist in compound heterozygous
patients with porphyria, and this may relate to the epi-
sodic nature of the disease. The work with coexpression
of wild-type human PBGS and F12L, as well as the syn-
thetic variant R240A, proved that homo-oligomers of
PBGS can come apart, change shape, and reassemble into
a structurally and functionally different homo-oligomer.38,39
Because F12L and the designed synthetic human PBGS
variants R240A and W19A had shown that single–amino
acid mutations could dramatically alter the folding and
assembly of human PBGS,36,38,39 we addressed whether the
porphyria-associated ALAD alleles encode a PBGS with an
altered quaternary-structure (morpheein) equilibrium.
The present study demonstrated that each porphyria-
associated mutation shifts the human PBGS morpheein
equilibrium toward the hexamer. This demonstration pro-
vides a new way to think about genetic alterations that
compromise function but are not obviously at the enzyme
active site. Genetic mutations that shift a morpheein equi-
librium favor a distinct alternate quaternary assembly,
rather than an amorphous, “misfolded” state. Knowledge
of the structural difference between the more-active and
the less-active morpheein assemblies may provide a foun-
dation for correcting the structural and functional imbal-
ance. Other human proteins have been suggested to ex-
hibit morpheein-like characteristics,41 and it is possible
that natural genetic variations or disease states are related
to shifts in these morpheein equilibria. The human en-
zymes that, so far, have been suggested to exist as mor-
pheeins are the mitochondrial enzyme succinyl-CoA
transferase that functions in the metabolism of ketone
bodies; purine nucleoside phosphorylase, which is an im-
portant component of the purine salvage pathway; ribo-
nucleotide reductase, which is responsible for balancing
the production of deoxyribonucleotides for DNA repli-
cation; and the peroxiredoxins, which function in cell-
signaling pathways. Having established that the ALAD
alleles associated with ALAD porphyria all perturb the
morpheein equilibrium for human PBGS, we suggest that
the genetic diseases succinyl-CoA transferase deficiency
(MIM 245050),47 purine nucleoside phosphorylase defi-
ciency (MIM 164050),47 and those related to ribonucleo-
tide reductase or peroxiredoxins may also reflect pertur-
bation of the morpheein equilibria for these proteins and
constitute conformational diseases. A conformational dis-
ease resulting from perturbation of a morpheein equilib-
rium may be suspected in cases in which a homo-oligo-
meric protein structure is known and a disease-causing
missense mutation is known to be distant from the en-
zyme active site.
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